Phenylketonuria (PKU) Clinical Trials

Find Phenylketonuria (PKU) Clinical Trials Near You

A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria

Status: Recruiting
Location: See all (25) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylketonuria. Participants will be randomly assigned to receive either JNT-517 or placebo during an initial 6-week treatment period. After this period, eligible participants will receive JNT-517 for an additional 46 weeks.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 4
Healthy Volunteers: f
View:

• Male or female participants aged 4 years or older.

• Diagnosed with phenylketonuria.

• Have phenylalanine levels that meet study requirements.

• Meet study-specific requirements regarding current treatment for phenylketonuria.

• Willing and able to follow study dietary requirements.

• Weigh at least 12.5 kilograms.

• If able to become pregnant or father a child, willing to follow the study's contraception requirements.

• Any ongoing mental health condition must be stable before entering the study.

• Able to provide informed consent (or have consent provided by a parent or legal guardian, when applicable) and comply with study procedures.

Locations
United States
California
University of California Los Angeles (UCLA) School of Medicine
RECRUITING
Los Angeles
Florida
University of Florida (UF) Health Shands Hospital
RECRUITING
Gainesville
University of South Florida
RECRUITING
Tampa
Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING
Chicago
Oregon
Oregon Health and Science University
RECRUITING
Portland
Pennsylvania
University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh
RECRUITING
Pittsburgh
Tennessee
Vanderbilt University Medical Center
RECRUITING
Nashville
Texas
University of Texas Southwestern
RECRUITING
Dallas
University of Texas Health (UTHealth) Science Center at Houston
RECRUITING
Houston
Utah
Utah Health - The University of Utah Hospital
RECRUITING
Salt Lake City
Other Locations
Australia
Royal Adelaide Hospital
RECRUITING
Adelaide
Royal Melbourne Hospital
RECRUITING
Parkville
Mater Health - Mater Hospital Brisbane
RECRUITING
South Brisbane
Canada
M.A.G.I.C Clinic
RECRUITING
Calgary
France
Centre Hospitalier Régional Universitaire (CHRU) de Tours - Hôpital Bretonneau
RECRUITING
Tours
Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
RECRUITING
Mainz
Universitätsklinikum Münster
RECRUITING
Münster
Japan
Nihon University Hospital
RECRUITING
Chiyoda-ku
Osaka Metropolitan University Hospital
RECRUITING
Osaka
Fujita Health University
RECRUITING
Toyoake
Netherlands
Universitair Medisch Centra (AMC)- Amsterdam
RECRUITING
Amsterdam
Beatrix Children's Hospital
RECRUITING
Groningen
Poland
Pomorski Uniwersytet Medyczny w Szczecinie
RECRUITING
Szczecin
Spain
Hospital Universitario Ramón y Cajal
RECRUITING
Madrid
Hospital Clinico Universitario de Santiago de Compostela
RECRUITING
Santiago De Compostela
Contact Information
Primary
Otsuka Call Center
Otsuka-ProfessionalServices@otsuka-us.com
844-687-8522
Time Frame
Start Date: 2025-10-20
Estimated Completion Date: 2028-04-01
Participants
Target number of participants: 120
Treatments
Experimental: JNT-517 - High Dose
Participants will receive JNT-517 orally, twice daily (BID), with dosing determined by age, for 6 weeks in Period 1, followed by JNT-517 orally, BID for 46 weeks in Period 2.
Experimental: JNT-517 - Low Dose
Participants will receive JNT-517 orally, BID, with dosing determined by age, for 6 weeks in Period 1, followed by JNT-517 orally for 46 weeks in Period 2.
Placebo_comparator: Placebo
Participants will receive JNT-517 matching placebo orally, BID for 6 weeks in Period 1, followed by JNT-517 orally, BID for 46 weeks in Period 2.
Related Therapeutic Areas
Sponsors
Leads: Otsuka Pharmaceutical Development & Commercialization, Inc.

This content was sourced from clinicaltrials.gov